UroGen Pharma Ltd’s recently made public that its Chief Medical Officer Schoenberg Mark unloaded Company’s shares for reported $0.17 million on Mar 18 ’24. In the deal valued at $14.05 per share,12,000 shares were sold. As a result of this transaction, Schoenberg Mark now holds 139,437 shares worth roughly $2.03 million.
Then, Smith Jason Drew sold 4,993 shares, generating $78,590 in total proceeds. Upon selling the shares at $15.74, the General Counsel now owns 18,824 shares.
Before that, Schoenberg Mark sold 3,789 shares. UroGen Pharma Ltd shares valued at $59,639 were divested by the Chief Medical Officer at a price of $15.74 per share. As a result of the transaction, Schoenberg Mark now holds 149,423 shares, worth roughly $2.17 million.
Jefferies downgraded its UroGen Pharma Ltd [URGN] rating to a Hold from a a Buy in a research note published on February 08, 2023; the price target was decreased to $10 from $35. A number of analysts have revised their coverage, including Berenberg’s analysts, who began to cover the stock in late April with a ‘”a Buy”‘ rating. H.C. Wainwright also remained covering URGN and reiterated its “Buy” recommendation on April 16, 2020. H.C. Wainwright maintained its rating on April 13, 2020. It rated URGN as “a Buy”.
Price Performance Review of URGN
On Tuesday, UroGen Pharma Ltd [NASDAQ:URGN] saw its stock jump 1.11% to $14.53. Over the last five days, the stock has gained 0.28%. UroGen Pharma Ltd shares have fallen nearly -3.13% since the year began. Nevertheless, the stocks have risen 44.72% over the past one year. While a 52-week high of $24.13 was reached on 02/16/24, a 52-week low of $8.69 was recorded on 04/11/24. SMA at 50 days reached $16.09, while 200 days put it at $15.10. A total of 0.22 million shares were traded, compared to the trading of 0.28 million shares in the previous session.
Levels Of Support And Resistance For URGN Stock
The 24-hour chart illustrates a support level at 14.14, which if violated will result in even more drops to 13.76. On the upside, there is a resistance level at 14.88. A further resistance level may holdings at 15.24. The Relative Strength Index (RSI) on the 14-day chart is 48.64, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.22, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 30.99%. Stochastics %K at 58.79% indicates the stock is a holding.
The most recent change occurred on January 09, 2020 when National Securities began covering the stock and recommended ‘”a Neutral”‘ rating along with a $37 price target.
